Anlotinib Tislelizumab Irinotecan

PreclinicalSmall molecule

Anlotinib Tislelizumab Irinotecan is one of 15 small molecule programs targeting Tislelizumab. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TislelizumabUnknown status

TislelizumabPreclinical

Unknown status

Competition

Competitive Landscape

15 competitors in Tislelizumab

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

15 2

Camptosar

Pfizer

Phase 2

1 3

LUNSUMIO

Roche

Phase 2

1 4

Mekinist

Novartis

Phase 2

1 5

Eloxatin

Teva

Phase 2

1 6

Taxol

Teva

Phase 2

1 7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Phase 2

1 8

Gemzar

Johnson & Johnson

Phase 1

1 9

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 10

Inderal

WWyeth-Lederle Vaccines

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tislelizumab1 trial

Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

Unknown status·HHaibo Zhang·N/A·NCT05027100·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anlotinib Tislelizumab Irinotecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anlotinib Tislelizumab Irinotecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anlotinib Tislelizumab Irinotecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haibo Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHaibo Zhang

Anlotinib Tislelizumab Irinotecan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tislelizumab1 trial

References

Drug Info

Quick Facts

Related News